{"id":765688,"date":"2023-06-23T08:03:30","date_gmt":"2023-06-23T12:03:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/"},"modified":"2023-06-23T08:03:30","modified_gmt":"2023-06-23T12:03:30","slug":"biovie-set-to-join-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes"},"content":{"rendered":"
\n

CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that the Company will be added as a member of the US small-cap Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000\u00ae Index, which remains in place for one year, is based on membership in the broad-market Russell 3000\u00ae Index. The stock also was automatically added to the appropriate growth and value indexes.<\/p>\n

Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The Russell 3000\u00ae Index serves as the U.S. component to the Russell Global Index, and the Russell 2000\u00ae Index is a subset of the smallest 2,000 components of the Russell 3000\u00ae Index. FTSE Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.<\/p>\n

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell\u2019s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.<\/p>\n

For more information on the Russell 2000\u00ae Index and the Russell indexes reconstitution, go to the \u201cRussell Reconstitution\u201d section on the FTSE Russell website<\/a>.<\/p>\n

\n About FTSE Russell:<\/strong>
\n
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.<\/p>\n

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20.1 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.<\/p>\n

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.<\/p>\n

FTSE Russell is wholly owned by London Stock Exchange Group.<\/p>\n

For more information, visit www.ftserussell.com<\/a>.<\/p>\n

\n About BioVie\u00a0<\/strong>\u00a0<\/p>\n

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company\u2019s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer\u2019s and Parkinson\u2019s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer\u2019s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer\u2019s. A Phase 2 study of NE3107 in Parkinson\u2019s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in \u201cmorning on\u201d symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company\u2019s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http:\/\/www.bioviepharma.com\/<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\u00a0<\/p>\n

\n This press release contains forward-looking statements, including statements regarding the Company\u2019s strategy, plans and objectives, such as statements regarding the Company\u2019s anticipated timeline for announcing results from the NE3107 Phase 3 potential pivotal trials.\u202fForward-looking statements may generally be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due risks associated with conducting and completing clinical trials, including our reliance on third parties to conduct our clinical trials, to successfully defend potential future litigation, our ability to raise capital when needed on reasonable terms, changes in local or national economic conditions\u202fas well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.\u202f <\/em>\n <\/p>\n

\n
\n For Investor Relations Inquiries:<\/em>
\n <\/strong>\u00a0<\/p>\n\n\n
Contact:\u00a0
Bruce Mackle<\/strong>\u00a0
Managing Director<\/em>\u00a0
LifeSci Advisors, LLC<\/strong>\u00a0
bmackle@lifesciadvisors.com<\/a><\/u><\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that the Company will be added as a member of the US small-cap Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000\u00ae Index, which remains in place for one year, is based on membership in the broad-market Russell 3000\u00ae Index. The stock also was automatically added to the appropriate growth and value indexes. Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks … <\/p>\n

Continue reading “BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765688","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that the Company will be added as a member of the US small-cap Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000\u00ae Index, which remains in place for one year, is based on membership in the broad-market Russell 3000\u00ae Index. The stock also was automatically added to the appropriate growth and value indexes. Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks … Continue reading "BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T12:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\",\"datePublished\":\"2023-06-23T12:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==\",\"datePublished\":\"2023-06-23T12:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","og_description":"CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced that the Company will be added as a member of the US small-cap Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000\u00ae Index, which remains in place for one year, is based on membership in the broad-market Russell 3000\u00ae Index. The stock also was automatically added to the appropriate growth and value indexes. Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks … Continue reading \"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-23T12:03:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes","datePublished":"2023-06-23T12:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/","name":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==","datePublished":"2023-06-23T12:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzIzMiM1NjYxMzUxIzUwMDA3OTY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-set-to-join-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioVie Set to Join the Russell 2000\u00ae and Russell 3000\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765688"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765688\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}